The humanised trispecific antibody is undergoing Phase I clinical trials in the US and China in subjects with relapsed or refractory multiple myeloma (MM). Simcere Zaiming will gain an upfront ...

prompting the creation of multispecific antibodies, which include bispecific, trispecific, and tetraspecific antibodies. Among these, bispecific antibodies, capable of binding to two distinct epitopes ...

AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500. The humanised trispecific antibody is undergoing Phase I ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform.

SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S. SIM0500 is a humanized trispecific antibody that targets ...

entered an option to license agreement to develop SIM0500, an investigational new drug candidate in Phase 1 trials in relapsed or refractory multiple myeloma (MM), in both China and the U.S. SIM0500 ...